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COVID-19 has highlighted the lethal consequences of immunothrombosis; i.e. the cross-talk 
between coagulation, inflammation and the innate immune system. These patients have 
significant immune cell death1, which can release pro-coagulant2 and cytotoxic3 histones. 
Histones are small positively charged proteins, typically found within the cell nucleus, which 
bind to negatively charged DNA. We hypothesize that circulating histones play a central role 
in critically ill COVID-19 patients. This translational study demonstrates that admission 
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histone levels were significantly elevated with increasing severity of COVID-19 infection 
(Mild, median=2.6µg/ml [IQR=0.7-7.6], Moderate, 10.5µg/ml [3.5-27.2], Critical, 20.0µg/ml 
[6.2-33.0], Non-survivors, 29.6µg/ml [11.2-60.0]; P<.001). Circulating histones associated 
with severe coagulopathy, inflammation and organ injury markers, including cardiac 
troponin. Extracellular histone levels on admission are associated with poor outcomes and 
independently predict 28-day mortality of hospitalised COVID-19 patients. This is the first 
report to indicate that circulating histones, released following immune cell death, may play a 
central pathological role in severe SARS-CoV-2 infection. 
COVID-19 was the cause of more than 2 million deaths worldwide by February 20214, 
resulting from respiratory and multi-organ failure5, with evidence of pulmonary thrombosis at 
post-mortem6. These patients have extensive immune cell death1, a strong acute-phase 
inflammatory response and coagulopathy, as well as cardiac injury1, 5. Cell death can release 
histones, and extracellular histones are cytotoxic, pro-inflammatory7 and pro-coagulant2, 
leading to pulmonary thrombosis8. Extracellular histones also trigger interleukin-6 (IL-6)  
release to induce acute phase response, including elevation of C-reactive protein (CRP), 
which in turn reduces histone toxicity9. High levels of circulating histones initiate an 
alternative coagulation pathway during sepsis2, mediate multiple organ injury3  and correlate 
with adverse clinical outcomes, including death10. We therefore hypothesized that high levels 
of histones are present in severe SARS-CoV-2 infection, and act as major mediators of 
coagulopathy and mortality in COVID-19 disease.  
In this study, adult COVID-19 patients (n=113) were recruited at the Royal Liverpool 
University Hospital from 30th March 2020 to 16th May 2020, using the ISARIC WHO 
Clinical Characterisation Protocol for Severe Emerging Infections in the UK. Inclusion 
criteria were: (1) swab positive or high likelihood of infection OR (2) ≥1 of the following 
symptoms: fever ≥38⁰C, new cough, dyspnoea OR tachypnoea AND admitted to a healthcare 
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facility11. Patients were categorised into four groups: 1) Mild (minor respiratory symptoms to 
exclude shortness of breath OR incidental finding, where the patient required admission to 
hospital for reasons other than COVID-19 [such as for frailty] and was otherwise 
asymptomatic of COVID-19), 2) Moderate (dyspnoea, i.e. patient symptomatic with 
shortness of breath OR hypoxia, defined by oxygen saturations on pulse oximeter of ≤93% or 
requiring supplementary oxygen to maintain oxygen saturations ≥96%), 3) Critical disease 
(respiratory failure requiring the administration of continuous positive airway pressure 
[CPAP] to maintain oxygen saturations ≥96% or invasive ventilation in a critical care setting) 
and 4) Non-survivors (died within 28 days of hospital admission). Circulating histones were 
quantified in patient plasma on admission (as described previously8, 12) and associations with 
severity of infection, coagulation, inflammatory and organ injury markers were analysed. 
Severity of infection was determined by the patient’s most severe clinical state throughout the 
hospital admission according to the previously described definitions. Cytokines were 
measured using a Luminex-based bead array as per manufacturer’s instructions [Thermo-
Fisher Scientific]. Outcome measures included ventilator support days, length of hospital 
stay, and 28-day mortality. Ethical approval was given by the South Central - Oxford C 
Research Ethics Committee in England (Ref 13/SC/0149), the Scotland A Research Ethics 
Committee (Ref 20/SS/0028), and the WHO Ethics Review Committee (RPC571 and 
RPC572, 25 April 2013. Local approval was granted by the North West - Haydock Research 
Ethics Committee (REC reference 20/NW/0332). 
The Kruskall-Wallis test was used for comparison of continuous variables, presented as 
median [interquartile range; IQR]; the Fishers Exact/Chi squared test for comparison of 
categorical variables, presented as counts [percentage]. Circulating histone levels were 
measured by Western Blot, using purified histone as the standard, and analysed either as 
continuous variables or categorised based on a previously determined threshold for 
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cytotoxicity (30µg/mL)3, 7. Mann-Whitney U test was used to compare categorical histone 
levels to continuous clinical variables. Correlation analysis was performed using Spearman’s 
rank. Receiver Operating Characteristic (ROC) curve analysis and multivariate regression 
(adjusted for age, gender, ethnicity and co-morbidities) assessed admission histone levels in 
predicting 28-day mortality. Kaplan-Meier survival curve analysis was performed to analyse 
the probability of mortality over time. Statistical tests were performed on SPSS (IBM, 
version 25). A 2-tailed P value of <.05 was considered significant. 
One hundred and thirteen COVID-19 patients were studied (Table 1): median age 65.0 years 
[IQR=51.0-78.0 years], 65 patients were male [57.5%], 96 of white ethnicity [85.0%]. 
Disease severity was associated with coagulation activation (Table 1), characterised by 
elevated D-dimer (P=.017) and prolonged prothrombin time (P=.005), and a pro-
inflammatory phenotype characterised by elevated CRP (P<.001) and IL-6 (P=.002) on 
hospital admission, as well as with hypoxia and cardiac injury (Table 1). Median hospital 
length of stay was 10 days [IQR, 3-20 days] and 25 patients [22.1%] died within 28 days.  
Circulating histone levels on admission were significantly elevated in COVID-19 patients 
compared to normal controls and were associated with increasing severity of infection 
(Figure 1A and B; Healthy controls, median=2.9µg/ml [IQR=1.5-3.3]; Mild, 2.6µg/ml [0.7-
7.6]; Moderate, 10.5µg/ml [3.5-27.2]; Critical, 20.0µg/ml [6.2-33.0]; Non-survivors, 
29.6µg/ml [11.2-60.0]; P<.001). Circulating histone levels strongly correlated with D-dimer 
levels (R=.606), indicating potential involvement of extracellular histones in COVID-19 
coagulopathy. Positive association with organ injury markers, including bilirubin (R=.531), 
creatinine (R=.501) and cardiac troponin (R=.486), indicates the possible role of histone-
induced cytotoxicity in multiple organ injury. Strong associations with fibrinogen (R=.632), 
CRP (R=.735) and IL-6 (R=.677) confirmed histone-initiated acute phase response9. Negative 
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correlation with lymphocyte count (R=-.446) suggests that lymphocyte and other immune 
cell death might be a major source of circulating histones in COVID-19 infection.  
Using a 30µg/ml cytotoxic histone threshold3, 7, patients over the threshold (n=29) had 
significantly higher D-dimer (2267.0ng/ml [1227.0-5235.0] vs 1128.0ng/ml [589.0-1844.3], 
P=.001), fibrinogen (6.6g/L [4.6-7.6] vs 4.8g/L [3.9-5.7], P=.012), IL-6 (226.2pg/ml [90.6-
518.9] vs 71.8pg/ml [35.2-111.4], P<.001) and CRP levels (186mg/L [108.5-247.5] vs 
48.0mg/L [10.0-107.5], P<.001) than those patients below the threshold (Table 2). These 
patients also had significantly reduced SpO2 than those with circulating histones <30 µg/ml 
(oxygen saturations 92.0% [85.8-94.0] vs 95.0% [93.5-97.0], P=.001), required critical care 
admission (P<.001), with longer duration of mechanical ventilation (R=.635) and hospital 
stay (R=.654).  
Circulating histone levels were significantly higher in non-survivors than those who survived 
(29.6µg/ml [11.2-60.0] vs 8.6 µg/ml [3.1-24.8], P=.002), and accordingly, patients with 
histones >30µg/ml were more likely to die (13/29 [44.8%] vs 12/84 [14.3%], P=.001). 
Patients who died were significantly older than those who survived (Table 2, 76 years [66-86] 
vs 59 years [46-72] P<.001). Compared to survivors, non-survivors had evidence of 
consumptive coagulopathy with lower platelet counts (P=.003), prolonged prothrombin time 
(P=.028), elevated D-dimer (P=.017) and reduced antithrombin levels (P=.048). Furthermore, 
in non-survivors, lymphocyte counts (P=.001), and oxygen saturations (P=.005) were 
significantly reduced, and IL-6 (P=.021), CRP (P=.013), troponin (P<.001), bilirubin 
(P=.041) and creatinine (P=.024) were elevated when compared to survivors (Table 2).   
Univariate analysis using continuous circulating histones demonstrated that rising histone 
levels were associated with mortality (odds ratio =1.031 (95% CI=1.013-1.049, P=.001). 
Using categorical data where patients were stratified based on ≥30µg/ml threshold3, 7, similar 
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results were obtained (Figure 1C, OR=4.875 (95% CI=1.879-12.649, P=.001), demonstrating 
that patients with high circulating histone levels on admission had higher risks of mortality. 
Subsequent multivariate analysis demonstrated that histones were independently associated 
with mortality after adjustment for age, gender, ethnicity and co-morbidity, when histone 
levels were treated as either continuous (odds ratio=1.032; 95% CI=1.013-1.051, P=.001) or 
categorical variables (odds ratio=5.404; 95% CI=1.852-15.770, P=.002). ROC curve analysis 
shows an area under the curve [AUC] of .708 (95% CI=.589-.827, P=.002). Kaplan-Meier 
survival curve demonstrated a significant increase in the probability of mortality during 28-
days in patients with histones ≥30µg/ml (Figure 1D, P=.001). 
Coagulopathy has emerged as a key feature of severe COVID-19 and has been linked to 
increased mortality13. It has been documented that extracellular histones, released following 
cell death, are drivers of coagulation by activating platelets7, generating thrombin2 and 
damaging endothelial cells8 to induce coagulopathy in critical illness3. This is the first report 
to demonstrate high levels of circulating histones in SARS-CoV-2 infection, with levels 
strongly associated with coagulopathy, suggesting their involvement in thrombosis in severe 
cases14.  
High levels of circulating histones reflect the extent of cellular death, such as lymphopenia or 
NETosis15, which may be a major source of circulating histones in COVID-19. Histone 
release following cell death triggers IL-6 release to induce the acute-phase response8. We 
found that circulating histone levels significantly correlated with IL-6 and acute-phase 
protein levels, including fibrinogen and CRP, indicating histone-induced acute phase 
response in patients with COVID-19.  
Extracellular histones disrupt cell membranes through phospholipid binding to induce 
cytotoxic effects on cells, including endothelial cells8 and cardiomyocytes12. This study 
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demonstrates circulating histones associated with cardiac injury, which is frequently seen 
with severe COVID-19, and associated with poor outcomes5. Therefore, the cytotoxic and 
pro-coagulant properties of circulating histones may be an underlying molecular mechanism 
contributing to disease severity and poor outcomes (Figure 1E).  
In conclusion, this is the first report to quantify high levels of circulating histones in viral 
infection and demonstrate that extracellular histones play a central role in the development of 
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Total Mild Moderate Critical Non-survivors 
P  
valuea 
Total number (n) 113 30 38 20 25 .. 
Demographics & Comorbidities       
Age (years), Median [IQR] 65.0 [51.0, 78.0] 63.5 [42.0, 70.0] 67.0 [57.5, 81.5] 51.0 [42.8, 54.5] *,¥ 76.0 [66.0, 86.0] *,† <.001 
Male, No. [%] 65 [57.5] 15 [50.0] 20 [52.6] 14 [70.0] 16 [64.0] .428 
White ethnicity, No. [%] 96 [85.0] 26 [86.7] 35 [92.1] 11 [55.0] 24 [96.0] .001 
Smoking history, No. [%] 38 [33.6] 10 [33.3] 16 [42.1] 4 [20.0] 8 [32.0] .033 
Hypertension, No. [%] 36 [31.9] 8 [26.7] 12 [31.6] 5 [25.0] 11 [44.0] .474 
Asthma/COPD, No. [%] 29 [25.7] 14 [46.7] 10 [26.3] 1 [5.0] 4 [16.0] .005 
Diabetes mellitus, No. [%] 29 [25.7] 5 [16.7] 10 [26.3] 5 [25.0] 9 [36.0] .443 
Ischaemic heart disease, No.[%] 16 [14.2] 3 [10.0] 8 [21.1] 0 [0.0] 5 [20.0] .116 
Chronic kidney disease, No. [%] 15 [13.3] 3 [10.0] 10 [26.3] 0 [0.0] 2 [8.0] .025 
       
Histones (µg/ml), Median [IQR] 10.8 [3.2, 29.9] 2.6 [0.7, 7.6] 10.5 [3.5, 27.2] * 20.0 [6.2, 33.0] * 29.6 [11.2, 60.0] *,¥ <.001 
Peripheral blood cell counts       
White blood cells (x109/L), Median [IQR] 8.5 [5.8, 11.8] 8.2 [6.6, 10.7] 9.8 [5.9, 12.3] 8.1 [6.5, 10.8] 8.1 [5.2, 11.3] .623 
Neutrophils (x109/L), Median [IQR]        6.4 [4.0, 9.3] 5.9 [3.8, 8.0] 7.0 [4.1, 9.8] 6.4 [4.0, 9.0] 7.2 [4.0, 11.2]  .748 
Lymphocytes (x109/L), Median [IQR] 1.0 [0.7, 1.6] 1.2 [0.8, 1.7] 1.1 [0.8, 1.4] 1.1 [0.9, 2.1] 0.7 [0.4, 1.1] *,¥,† .009 
Haemoglobin (g/L), Median [IQR] 129.0 [117.8, 145.3] 126.0 [119.0, 145.0] 123.0 [113.8, 139.8] 134.5 [131.0, 146.0] ¥ 136.0 [107.0, 147.0] .122 
Platelets (x109/L), Median [IQR] 236.5 [170.3, 296.0] 253.0 [177.0, 311.0] 243.5 [113.8, 139.8] 250.5 [207.3, 299.3] 174.0 [124.0, 250.0] *,¥,† .026 
Coagulation parameters       
PT (seconds), Median [IQR] 13.2 [12.1, 14.4] 12.1 [11.2, 13.0] 13.1 [12.1, 14.4] *  13.4 [13.1, 14.2] * 14.1 [12.4, 20.7] * .005 
aPTT (seconds), Median [IQR] 30.6 [28.2, 33.6] 31.0 [28.9, 32.7] 30.5 [28.3, 32.6] 32.0 [29.1, 33.7] 30.0 [28.2, 37.6] .775 
Fibrinogen (g/L), Median [IQR] 4.8 [3.9, 6.5] 4.2 [2.8, 5.4] † 4.8 [4.4, 6.7] 6.5 [5.4, 6.6] * 4.5 [3.1, 4.9] † .010 
D-dimer (ng/ml), Median [IQR] 1227.0 [687.0, 2141.5] 755.5 [431.5, 1744.0] 1315.0 [832.5, 2176.3] * 950.0 [602.0, 1728.0] 1630.0 [1117.0, 4334.0] *,† .017 
Antithrombin (%), Median [IQR] 80.0 [61.0, 100.0] 81.0 [57.5, 98.5] 80.0 [61.5, 97.5] 98.0 [80.3, 114.8] *¥ 70.0 [59.0, 87.0] † .024 
Pro-inflammatory markers       
IL-6 (pg/ml), Median [IQR] 79.0 [40.5, 131.9] 53.2 [15.0, 83.1] 70.5 [41.9, 115.0] 166.7 [75.6, 214.7] * 107.7 [81.3, 269.8] *,¥ .002 
C-reactive protein (mg/L), Median [IQR] 61.0 [21.0, 153.5] 16.0 [3.5, 53.8] 52.0 [23.3, 146.3] * 145.0 [97.0, 202.5] *,¥ 105.0 [71.0, 192.0] *,¥ <.001 
Organ injury markers       
Troponin T (ng/L), Median [IQR] 12.0 [5.0, 35.0] 8.0 [5.0, 16.0] 16.0 [6.8, 47.3] * 6.5 [5.0, 10.5] ¥ 35.0 [17.0, 58.0] *,† <.001 
Bilirubin (µ mol/L), Median [IQR] 9.0 [6.0, 14.0] 8.0 [4.5, 13.0] 8.0 [6.0, 15.0] 9.0 [6.0, 12.5] 12.0 [8.0, 16.5] * .142 
ALT (U/L), Median [IQR] 25.5 [14.5, 45.0] 21.0 [11.5, 55.0] 19.0 [11.5, 38.0] 33.5 [29.0, 59.5] ¥ 28.5 [15.8, 44.3] .163 
Creatinine (µmol/L), Median [IQR] 77.0 [63.0, 105.0] 74.5 [62.0, 82.3] 78.0 [60.8, 104.3] 80.0 [57.8, 96.0] 102.0 [71.0, 180.0] * .125 
SpO2 (%), Median [IQR] 95.0 [92.0, 97.0] 97.0 [95.0, 98.0] 94.5 [92, 96] * 94.0 [92.0, 96.5] * 92.0 [78.5, 96.0] * <.001 
Outcomes       
Length of stay (days), Median [IQR] 10.0 [3.0, 20.0] 2.0 [1.0, 13.8] 10.0 [6.0, 22.0] * 17.0 [9.5, 43.8] * .. <.001 
Ventilator support (days), Median [IQR] 0.0 [0.0, 0.0] 0.0 [0.0, 0.0] 0.0 [0.0, 0.0] 2.0 [0.0, 9.3] 0.0 [0.0, 8.0] <.001 
 
Table 1. Demographics, peripheral blood measurements and outcomes for disease severity groups in COVID-19 infection. a P value for comparisons mild vs moderate 









Histones <30µg/ml Histones ≥30µg/ml 
P 
valueb 
Total number (n) 88 25 .. 84 29 .. 
Demographics & Comorbidities       
Age (years), Median [IQR] 59.0 [45.8, 72.3] 76.0 [66.0, 86.0] <.001 63.0 [47.8, 76.0] 66.0 [57.0, 80.0] .224 
Male, No. [%] 49 [55.7] 16 [64.0] .458 48 [57.1] 17 [58.6] .890 
White ethnicity, No. [%] 72 [81.8] 24 [96.0] .113 73 [86.9] 23 [79.3] .324 
Smoking history, No. [%] 30 [34.1] 8 [32.0] .845 28 [33.3] 10 [34.5] .910 
Hypertension, No. [%] 25 [28.4] 11 [44.0] .140 28 [33.3] 8 [27.6] .567 
Asthma/COPD, No. [%] 25 [28.4] 4 [16.0] .301 25 [29.8] 4 [13.8] .138 
Diabetes mellitus, No. [%] 20 [22.7] 9 [36.0] .180 21 [25.0] 8 [27.6] .783 
Ischaemic heart disease, No. [%] 11 [12.5] 5 [20.0] .343 13 [15.5] 3 [10.3] .758 
Chronic kidney disease, No. [%] 13 [14.8] 2 [8.0] .515 11 [13.1] 4 [13.8] >.999 
       
Histones (µg/ml), Median [IQR] 8.6 [3.1, 24.8] 29.6 [11.2, 60.0] .002 6.1 [2.0, 13.5] 51.6 [38.2, 72.8] <.001 
Peripheral blood cell counts       
White blood cells (x109/L), Median [IQR] 8.7 [6.1, 11.8] 8.1 [5.2, 11.3] .387 8.0 [5.7, 11.0] 9.8 [6.7, 13.3] .084 
Neutrophils (x109/L), Median [IQR]  6.2 [4.0, 8.9] 7.2 [4.0, 11.2]  .563 5.7 [3.6, 8.2] 9.1 [6.1, 12.2] .001 
Lymphocytes (x109/L), Median [IQR] 1.1 [0.8, 1.7] 0.7 [0.4, 1.1] .001 1.2 [0.8, 1.7] 0.8 [0.5, 1.1] .007 
Haemoglobin (g/L), Median [IQR] 128.0 [118.0, 144.0] 136.0 [107.0, 147.0] .740 128.0 [118.0, 145.0] 131.0 [116.0, 147.0] .740 
Platelets (x109/L), Median [IQR] 248.0 [181.0, 299.0] 174.0 [124.0, 250.0] .003 237.5 [174.3, 295.8] 215.0 [155.8, 296.8] .410 
Coagulation parameters       
PT (seconds), Median [IQR] 13.0 [11.8, 14.1] 14.1 [12.4, 20.7] .028 12.8 [11.8, 14.0] 13.8 [13.3, 15.6] .005 
aPTT (seconds), Median [IQR] 30.9 [28.4, 32.9] 30.0 [28.2, 37.6] .858 30.7 [28.7, 34.0] 29.5 [28.0, 32.6] .268 
Fibrinogen (g/L), Median [IQR] 5.3 [4.1, 6.5] 4.5 [3.1, 4.9] .091 4.7 [3.9, 5.7] 6.6 [4.6, 7.6] .012 
D-dimer (ng/ml), Median [IQR] 1166.0 [619.0, 2038.0] 1630.0 [1117.0, 4334.0] .017 1128.0 [589.0, 1844.3] 2267.0 [1227.0, 5235.0] .001 
Antithrombin (%), Median [IQR] 83.0 [62.5, 102.5] 69.5 [55.8, 81] .048 82.0 [59.0, 100.4] 77.0 [69.0, 99.0] .971 
Pro-inflammatory markers       
IL-6 (pg/ml), Median [IQR] 73.9 [36.6, 125.4] 107.7 [81.3, 269.8] .021 71.8 [35.2, 111.4] 226.2 [90.6, 518.9] <.001 
C-reactive protein (mg/L), Median [IQR] 50.0 [15.3, 149.0] 105.0 [71.0, 192.0] .013 48.0 [10.0, 107.5] 186.0 [108.5, 247.5] <.001 
Organ injury markers       
Troponin T (ng/L), Median [IQR] 5.0 [10.0, 23.0] 35.0 [17.0, 58.0] <.001 10.0 [5.0, 24.0] 25.0 [9.8, 57.3] .011 
Bilirubin (µmol/L), Median [IQR] 8.0 [5.0, 13.0] 12.0 [8.0, 16.5] .041 8.0 [5.0, 13.0] 11.0 85.0, 16.3] .016 
ALT (U/L), Median [IQR] 25.0 [12.8, 45.0] 28.5 [15.8, 44.3] .727 20.5 [12.8, 38.3] 36.5 [25.5, 55.3] .062 
Creatinine (µ mol/L), Median [IQR] 76.0 [61.0, 96.8] 102.0 [71.0, 180.0] .024 76.0 [62.5, 99.3] 96.0 [65.0, 154.0] .127 
SpO2 (%), Median [IQR] 95.0 [93.0, 97.0] 92.0 [78.5, 96.0] .005 95.0 [93.5, 97.0] 92.0 [85.8, 94.0] .001 
Outcomes       
Length of stay (days), Median [IQR] 10.0 [3.0, 20.0] .. .. 8.0 [2.5, 15.5] 28.0 [13.0, 41.5] <.001 
Ventilator support (days), Median [IQR] 0.0 [0.0, 0.0] 0.0 [0.0, 0.0] .347 0.0 [0.0, 0.0] 0.0 [0.0, 8.0] <.001 
Mortality at 28 days, No. [%] 0 [0] 25 [100] <.001 12 [14.3] 13 [44.8] .001 
 
Table 2. Demographics, peripheral blood measurements and outcomes of COVID-19 patients. a P value for survivors vs non-survivors. b P value for toxic histone levels 




Figure 1. High levels of circulating histones on hospital admission are associated with 
disease severity and mortality in COVID-19. Typical western blots (A) and quantification 
(B) of histone levels in healthy controls (n=12), mild (n=30), moderate (n=38) and critical 
disease (n=20) and non-survivors (n=25) with COVID-19 infection. Circulating histone 
levels were higher with increasing disease severity (P<.001). Histone levels were higher in 
non-survivors compared to the moderate (P=.023), mild groups (P<.001) and to normal 
healthy controls (P<.001). Histone levels were higher in the critical group compared to mild 
groups (P<.001) and normal healthy controls (P<.001). Histone levels were higher in the 
moderate group compared to the mild group (P=.007) and normal healthy controls (P=.002).  
(C) Multivariate analysis of crude and adjusted odds ratios (with patients adjusted for age, 
gender, BAME ethnicity and comorbidities including smoking, hypertension, asthma/COPD, 
diabetes, ischaemic heart disease and chronic kidney disease). Circulating histone levels 
>30µg/ml were independently associated with 28-day mortality. (D) Kaplan-Meier survival 
curve for the probability of mortality during 28 days. Patients were stratified based on 
circulating histones levels on admission (<30µg/ml vs ≥30µg/ml). (E) Diagram to propose 
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